Sumitomo Pharma Switzerland

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Sumitomo Pharma Switzerland sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 3 currently recruiting 7 completed early-phase tilt top decile by trial count

Sumitomo Pharma Switzerland: 13 sponsored US clinical trials, 3 recruiting.

Sumitomo Pharma Switzerland sponsors 13 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 7 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Complete DiGeorge Syndrome, with 2 trials.

Top-decile sponsor footprint

Sumitomo Pharma Switzerland ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

13 total, page 1 of 1

RECRUITING Phase 3

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

NCT05862272
RECRUITING

Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring

NCT05739123
RECRUITING

Congenital Athymia Patient Registry

NCT05329935
ACTIVE NOT RECRUITING

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

NCT05739136
ACTIVE NOT RECRUITING Phase 3

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy

NCT04756037
COMPLETED

Farber Disease Natural History Study

NCT03233841
COMPLETED NA

Thymus Transplantation Safety-Efficacy

NCT01220531
COMPLETED Phase 1

Phase I/II Thymus Transplantation With Immunosuppression #950

NCT00579527
TERMINATED Phase 1

Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation

NCT00597441
COMPLETED Phase 1

Parathyroid and Thymus Transplantation in DiGeorge #931

NCT00566488
COMPLETED Phase 2

Thymus Transplantation Dose in DiGeorge #932

NCT00576836
COMPLETED Phase 1

Thymus Transplantation With Immunosuppression

NCT00579709
COMPLETED Phase 2

Thymus Transplantation in DiGeorge Syndrome #668

NCT00576407

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2
Phase 3 2

Therapeutic Areas

Complete DiGeorge Syndrome 2
Complete DiGeorge Anomaly 2
Pregnancy Complications 2
Pregnancy, High Risk 2
Pregnancy Related 2
DiGeorge Anomaly 1
Congenital Athymia 1
Uterine Fibroids 1
DiGeorge Syndrome 1
Contraception 1

What is open in the Sumitomo Pharma Switzerland pipeline

3 recruiting of 13 indexed (23% open); 7 completed (54%).

Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Complete DiGeorge Syndrome (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Sumitomo Pharma Switzerland: open-pipeline peers nationwide

Peers matched on 13 registered trials and 23% open enrollment, not the therapeutic-area sidebar.

Sumitomo Pharma Switzerland sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1015202530 0%5%10%15%20%25% Total trials Recruiting share Sumitomo Pharma SwitzerlandAdaptimmuneAgennixAkili Interactive LabsAlumisClemson UniversityLiberating TechnologiesRahul AggarwalSequenom
Sumitomo Pharma Switzerland sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Sumitomo Pharma Switzerland sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 23% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Sumitomo Pharma Switzerland page

13 registered trials is a research-attention snapshot, not an endorsement of Sumitomo Pharma Switzerland or any single study.

  • 3 of Sumitomo Pharma Switzerland's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Complete DiGeorge Syndrome is the condition Sumitomo Pharma Switzerland studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Complete DiGeorge Syndrome trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Sumitomo Pharma Switzerland pipeline card: 13 registered trials from official public datasets.Report a data error.